Confirming Rumors, Novartis Buys AAA To Boost Oncology Business
Integrating AAA will add to Novartis' expertise in diseases associated with neuroendocrine tumors and bring it a new technology platform for treating cancer.
You may also be interested in...
Novartis's Targeted Radioligand Improves OS And PFS In Prostate Cancer
Novartis’s PSMA-targeted radioligand has improved overall survival and progression-free survival in top-line results from the Phase III VISION study in prostate cancer, cementing the company's pioneering role in the therapeutic area.
Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact
BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.
Novartis Delighted With Xiidra Deal Despite Eye-Watering Price
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.